{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:59:22Z","timestamp":1786996762696,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.semarthrit.2020.08.004","type":"journal-article","created":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T10:56:21Z","timestamp":1596884181000},"page":"977-987","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Rituximab as a rescue treatment added on mycophenolate mofetil background therapy in progressive systemic sclerosis associated interstitial lung disease unresponsive to conventional immunosuppression"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1614-8064","authenticated-orcid":false,"given":"Javier","family":"Narv\u00e1ez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"LLuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1852-1723","authenticated-orcid":false,"given":"Maria","family":"Molina-Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanesa","family":"Vicens-Zygmunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricio","family":"Luburich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos Anibal","family":"Ya\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2358-6767","authenticated-orcid":false,"given":"Joan M.","family":"Nolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2020.08.004_bib0001","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0002","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0003","article-title":"Cyclophosphamide for connective tissue disease-associated interstitial lung disease","volume":"1","author":"Barnes","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0004","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1093\/rheumatology\/key151","article-title":"Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease","volume":"58","author":"Khanna","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0005","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2020.08.004_bib0006","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/rheumatology\/kel244","article-title":"Mycophenolate mofetil in diffuse cutaneous systemic sclerosis: a retrospective analysis","volume":"46","author":"Nihtyanova","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0007","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.40114","article-title":"Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of Scleroderma Lung Studies I and II","volume":"69","author":"Volkmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0008","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00408-013-9499-8","article-title":"Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study","volume":"191","author":"Panopoulos","year":"2013","journal-title":"Lung"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0009","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s10067-010-1498-z","article-title":"Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease","volume":"29","author":"Koutroumpas","year":"2010","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0010","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0011","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/art.24249","article-title":"B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis","volume":"60","author":"Lafyatis","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0012","doi-asserted-by":"crossref","first-page":"R54","DOI":"10.1186\/ar2965","article-title":"B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial","volume":"12","author":"Bosello","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0013","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1093\/rheumatology\/kep093","article-title":"Experience with rituximab in scleroderma: results from a 1-year, proof-of principle study","volume":"49","author":"Daoussis","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0014","first-page":"S17","article-title":"Effect of long-term treatment with rituximab on pulmonary function and skin fibrosis in patients with diffuse systemic sclerosis","volume":"30","author":"Daoussis","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0015","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.semarthrit.2014.09.002","article-title":"Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis","volume":"44","author":"Bosello","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0016","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.autrev.2015.07.008","article-title":"Rituximab in the treatment of patients with systemic sclerosis: our experience and review of the literature","volume":"14","author":"Giuggioli","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0017","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","article-title":"Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group","volume":"74","author":"Jordan","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0018","first-page":"S181","article-title":"Effects of rituximab in connective tissue disorders related interstitial lung disease","volume":"34","author":"Lepri","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0019","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.semarthrit.2016.10.003","article-title":"A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease","volume":"46","author":"Daoussis","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0020","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000384","article-title":"Rituximab in early systemic sclerosis","volume":"3","author":"Boonstra","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0021","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/RHU.0000000000000584","article-title":"Rituximab Experience in patients with long-standing systemic sclerosis\u2013associated interstitial lung disease","volume":"23","author":"Sari","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0022","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.autrev.2017.12.010","article-title":"Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review","volume":"17","author":"Thiebaut","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0023","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","article-title":"Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial","volume":"57","author":"Sircar","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0024","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/17843286.2017.1372244","article-title":"Two years follow-up of an open-label pilot study of treatment with rituximab in patients with early diffuse cutaneous systemic sclerosis","volume":"73","author":"Melsens","year":"2018","journal-title":"Acta Clin Belg"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0025","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2018-214816","article-title":"Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study","volume":"78","author":"Elhai","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0026","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/resp.12214","article-title":"Rituximab in severe, treatment-refractory interstitial lung disease","volume":"19","author":"Keir","year":"2013","journal-title":"Respirology"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0027","unstructured":"Departament de Salut Generalitat de Catalunya, 2018. Dictamen de la Comissi\u00f3 Farmacoterap\u00e8utica de la Medicaci\u00f3 Hospitalria de Dispensaci\u00f3 Ambulat\u00f2ria sobre l\u2019\u00fas de rituximab, tocilizumab i abatacept per al tractament fora d'indicaci\u00f3 de l'esclerosi sist\u00e8mica refractaria al tractament habitual.http:\/\/www.catsalut.gencat.cat\/web\/.content\/minisite\/catsalut\/proveidors_professionals\/medicaments_farmacia\/phf_mhda\/informes_camse\/esclerosi_sistemica\/Dictamen-CAMSES-web. PDF (last accessed 20 April 2020)."},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0028","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02026-2019","article-title":"Predictors of progression in systemic sclerosis patients with interstitial lung disease","author":"Distler","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0029","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"Classification criteria for systemic sclerosis: an American College of Rheumatology \/European League against Rheumatism collaborative initiative","volume":"65","author":"Van den Hoogen","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0030","first-page":"277","volume":"15","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0031","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.arbres.2013.04.001","article-title":"Spirometry. Spanish Society of Pulmonology and Thoracic Surgery (SEPAR)","volume":"49","author":"Garc\u00eda-R\u00edo","year":"2013","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0032","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"An official ATS\/ERS\/JRS\/ALATstatement:idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and Management Committee on Idiopathic Pulmonary Fibrosis","volume":"15","author":"Raghu","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.semarthrit.2020.08.004_bib0033","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","article-title":"An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline: treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline","volume":"192","author":"Raghu","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0034","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0035","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1378\/chest.07-2444","article-title":"Scleroderma Lung Study Research Group. High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease","volume":"134","author":"Goldin","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0036","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.autrev.2015.10.005","article-title":"Systemic sclerosis: new evidence reenforces the role of B cells","volume":"15","author":"Sakkas","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0037","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.imlet.2018.01.002","article-title":"Pathogenic roles of B lymphocytes in systemic sclerosis","volume":"195","author":"Yoshizaki","year":"2018","journal-title":"Immunol Lett"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0038","unstructured":"US National Library of Medicine. ClinicalTrials.gov. Evaluation of efficacy and safety of rituximab with mycophenolate mofetil in patients with interstitial lung diseases (EvER-ILD). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02990286. (last accessed 28 July 2020)."},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0039","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s13063-017-2016-2","article-title":"Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial","volume":"18","author":"Saunders","year":"2017","journal-title":"Trials"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0040","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3109\/03009741003781985","article-title":"Clinical and subclinical atherosclerosis in systemic sclerosis: consequences of previous corticosteroid treatment","volume":"39","author":"Vettori","year":"2010","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0041","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.3899\/jrheum.131210","article-title":"Scleroderma renal crisis","volume":"41","author":"Mouthon","year":"2014","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0042","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s10067-006-0302-6","article-title":"The natural course of progressive systemic sclerosis patients with interstitial lung involvement","volume":"26","author":"Benan","year":"2007","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0043","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/rheumatology\/kew195","article-title":"Rituximab in autoinmune connective tissue disease-associated interstitial lung disease","volume":"55","author":"Sharp","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0044","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1093\/rheumatology\/kex072","article-title":"Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre","volume":"56","author":"Md Yusof","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2020.08.004_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106389","article-title":"Safety and efficacy of Rituximab in systemic sclerosis: a systematic review and meta-analysis","volume":"83","author":"Tang","year":"2020","journal-title":"Int Immunopharmacol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220302201?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017220302201?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:04:42Z","timestamp":1758733482000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017220302201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0049017220302201"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.08.004","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab as a rescue treatment added on mycophenolate mofetil background therapy in progressive systemic sclerosis associated interstitial lung disease unresponsive to conventional immunosuppression","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2020.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}